Art. 4 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

Committee for Orphan Medicinal Products

In forcesince 7 Aug 2009cited 9×
1.

A Committee for Orphan Medicinal Products, hereinafter referred to as ‘the Committee’, is hereby set up within the Agency.

2.

The task of the Committee shall be:

(a)

to examine any application for the designation of a medicinal product as an orphan medicinal product which is submitted to it in accordance with this Regulation;

(b)

to advise the Commission on the establishment and development of a policy on orphan medicinal products for the European Union;

(c)

to assist the Commission in liaising internationally on matters relating to orphan medicinal products, and in liaising with patient support groups;

(d)

to assist the Commission in drawing up detailed guidelines.

3.

The Committee shall consist of one member nominated by each Member State, three members nominated by the Commission to represent patients' organisations and three members nominated by the Commission on the basis of a recommendation from the Agency. The members of the Committee shall be appointed for a term of three years, which shall be renewable. They may be accompanied by experts.

4.

The Committee shall elect its Chairman for a term of three years, renewable once.

5.

The representatives of the Commission and the Executive Director of the Agency or his representative may attend all meetings of the Committee.

6.

The Agency shall provide the secretariat of the Committee.

7.

Members of the Committee shall be required, even after their duties have ceased, not to disclose any information of the kind covered by the obligation of professional secrecy.

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. Now Pharm AG v European Commission.Decision

    At the outset, it must be borne in mind that Article 4(3) of Regulation No 141/2000 provides that the members of the Committee may be accompanied by experts.

    9 Sep 2010 · 62008TJ0074

  • Judgment of the General Court (Seventh Chamber) of 16 May 2019 (Extracts). GMP-Orphan (GMPO) v European Commission.Decision

    16 May 2019 · 62017TJ0733

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    On 13 October 2017, the applicant submitted to the European Medicines Agency (EMA) and, more specifically, to the Committee for Orphan Medicinal Products provided for in Article 4 of Regulation No 141/2000 (‘the COMP’), a report on the …

    23 Sep 2020 · 62019TJ0549

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    … particular, Articles 11, 12(3), 13(3), 14(11), 24, 26, 57(1), point (1), 57(2), 76 and 80 of Regulation No 726/2004, Article 4(7) of Regulation No 141/2000 and Articles 5(3), 6(3) and 8 of Regulation No 507/2006 — establish a specific …

    20 Jul 2016 · 62015TO0718(02)

  • Judgment of the General Court (Seventh Chamber) of 22 March 2018. Shire Pharmaceuticals Ireland Ltd v European Medicines Agency.Decision

    Thus, it is the responsibility of the Committee on Orphan Medicinal Products to assess whether the characteristics of Idursulfase-IT are likely to be of significant benefit to patients suffering from the condition at issue within the …

    22 Mar 2018 · 62016TJ0080

  • Order of the Court (Ninth Chamber) of 11 June 2020. GMP-Orphan (GMPO) v European Commission.Decision

    On 20 September 2016, the appellant submitted a report to the EMA’s Committee for Orphan Medicinal Products, provided for in Article 4 of Regulation No 141/2000 (‘the COMP’), on the maintenance of the designation of Cuprior as an …

    11 Jun 2020 · 62019CO0575

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v PTC Therapeutics International Ltd.Decision

    In the first place, all documents submitted in connection with an MA application and, in particular, clinical and non-clinical studies, such as the report at issue, should enjoy a general presumption of confidentiality under Regulation No …

    1 Mar 2017 · 62016CO0513

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    Under Article 56(1)(c) of Regulation No 726/2004 and Article 4(2)(a) and Article 5(5) and (12)(b) of Regulation No 141/2000, the Committee for Orphan Medicinal Products (COMP) of the EMA is responsible for examining any application for the …

    24 Sep 2025 · 62022TJ0483

  • Judgment of the Court (Eighth Chamber) of 29 July 2019. European Medicines Agency v Shire Pharmaceuticals Ireland Ltd.Decision

    However, it should be noted that verification of the criteria in Article 3(1) of Regulation No 141/2000 does not fall within the scope of the EMA’s review of the validity of the application for designation. Pursuant to Article 4 and …

    29 Jul 2019 · 62018CJ0359